CTOs on the Move

Onyx Pharmaceuticals

www.onyx.com

 
At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve.   By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.onyx.com
  • 249 E. Grand Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.266.0000

Executives

Name Title Contact Details

Similar Companies

International Partnership for Microbicides

Developing HIV prevention products for women worldwide

Curie Therapeutics

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie`s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie`s mission is to revolutionize the use of radiomedicines in cancer.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

BASS Medical Group

Headquartered in Walnut Creek, CA, BASS Medical Group is the Greater Bay Area’s leading healthcare specialist provider. With over 300 providers, 200 locations, & 42 specialties, BASS provides state-of-the-art care in a family setting. Known for its sma...

Cynapsus Therapeutics

Cynapsus Therapeutics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.